Cerebrospinal fluid liquid biopsies can enable the characterization and monitoring of medulloblastoma. The analysis of copy-number variations in circulating tumour DNA present in these samples can be used as a biomarker to determine the presence of measurable residual disease, and facilitate the optimal treatment and clinical management of patients with medulloblastoma.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hovestadt, V. et al. Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nat. Rev. Cancer 20, 42–56 (2020).
Diaz, L. A. Jr & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579–586 (2014).
De Mattos-Arruda, L. et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun. 6, 8839 (2015).
Martínez-Ricarte, F. et al. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid. Clin. Cancer Res. 24, 2812–2819 (2018).
Escudero, L. et al. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. Nat. Commun. 11, 5376 (2020).
Bobillo, S. et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica 106, 513–521 (2021).
Seoane, J., De Mattos-Arruda, L., Le Rhun, E., Bardelli, A. & Weller, M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann. Oncol. 30, 211–218 (2019).
Escudero, L., Martínez-Ricarte, F. & Seoane, J. ctDNA-based liquid biopsy of cerebrospinal fluid in brain cancer. Cancers 13, 1989 (2021).
Liu, A. P. Y. et al. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell 39, 1519–1530 (2021).
Sainte-Rose, C. et al. Management of hydrocephalus in pediatric patients with posterior fossa tumors: the role of endoscopic third ventriculostomy. J. Neurosurg. 95, 791–797 (2001).
Acknowledgements
The authors’ work is supported by Fundación Asociación Española contra el Cáncer (AECC), FERO, the Ramón Areces Foundation, the Cellex Foundation, BBVA (CAIMI), the ISCIII, FIS (PI19/00318) (J.S.) and the Juan de la Cierva Fellowship (L.E.).
Competing interests
J.S. has received research support from Hoffmann la Roche, Mosaic Biomedicals, Northern Biologics and Roche/Glycart, is a co-founder of Mosaic Biomedicals and has ownership interests in Mosaic Biomedicals and Northern Biologics. L.E. declares no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Seoane, J., Escudero, L. Cerebrospinal fluid liquid biopsies for medulloblastoma. Nat Rev Clin Oncol 19, 73–74 (2022). https://doi.org/10.1038/s41571-021-00590-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00590-1
